Charles River Laboratories International, Inc.

Charles River Laboratories International provides drug discovery, non-clinical development, and safety testing services globally. The company operates through three segments. The Research Models and Services segment produces and sells rodents, including purpose-bred rats and mice, for researchers, and offers services such as genetically engineered models, insourcing solutions, and research animal diagnostics. The Discovery and Safety Assessment segment provides in vitro and in vivo discovery services for novel drugs, biotherapeutics, and antibodies, along with safety assessment services like toxicology, pathology, and pharmacokinetics. The Manufacturing Solutions segment offers rapid quality control testing for pharmaceuticals and consumer products, including specialized testing of biologics and contract development and manufacturing services.

Charles River Laboratories International is listed on the New York Stock Exchange (NYSE) under the ticker symbol CRL. The company trades in US Dollars (USD), as it is headquartered in the United States. Being listed on a major US exchange provides liquidity and access to a broad investor base. The NYSE is one of the world's largest stock exchanges, and trading in USD allows investors to easily compare the company's performance with other US-listed equities in the healthcare sector.

Charles River Laboratories operates in the Healthcare sector, specifically within the Diagnostics & Research industry. This industry encompasses companies that provide analytical services, testing, and research support to pharmaceutical, biotechnology, and medical device firms. As a diagnostics and research company, Charles River plays a critical role in the drug development pipeline, offering services from early discovery through safety assessment and quality control. Its work helps clients accelerate the development of new therapies while ensuring compliance with regulatory standards.

Charles River Laboratories has three main business segments. The Research Models and Services segment produces and sells rodents and provides services like genetically engineered models, insourcing solutions, and diagnostic services for research animals. The Discovery and Safety Assessment segment offers in vitro and in vivo discovery services for drug candidates, including safety assessment services such as toxicology, pathology, and pharmacokinetics. The Manufacturing Solutions segment provides rapid quality control testing for pharmaceuticals and consumer products, as well as specialized testing of biologics and contract development and manufacturing services. These segments collectively support the entire drug development lifecycle.

Yes, Charles River Laboratories has strategic collaborations, including one with the Parker Institute for Cancer Immunotherapy. This partnership focuses on advancing cancer immunotherapy research by leveraging Charles River's expertise in drug discovery and safety testing. Additionally, the company collaborates with other organizations to support the development of cell therapies and novel treatments. These collaborations enhance Charles River's capabilities in cutting-edge therapeutic areas and strengthen its position as a leading provider of research services to the pharmaceutical and biotechnology industries.